ABSTRACT
Large-scale genotyping studies have identified over 70 single nucleotide polymorphisms (SNPs) associated with breast cancer (BC) risk. However, knowledge regarding genetic risk factors associated with the prognosis is limited. The aim of this study was therefore to investigate the prognostic effect of nine known breast cancer risk SNPs. BC patients (n = 1687) randomly sampled in an adjuvant, randomized phase III trial (SUCCESS A study) were genotyped for nine BC risk SNPs: rs17468277 (CASP8) , rs2981582 (FGFR2) , rs13281615(8q24), rs3817198 (LSP1) , rs889312 (MAP3K1) , rs3803662 (TOX3) , rs13387042(2q35), rs4973768 (SLC4A7) , rs6504950 (COX11) . Cox proportional hazards models were used to test the SNPs' association with overall survival (OS) and progression-free survival (PFS). Additional analyses were carried out for molecular subgroups. rs3817198 in LSP1 (lymphocyte-specific protein 1) was the only SNP that significantly influenced OS (p = 0.01) and PFS (p < 0.01) in the likelihood ratio test comparing the genetic survival model with the clinical survival model. In the molecular subgroups, triple-negative patients with two minor alleles in rs3817198 had a much better prognosis relative to OS (adjusted HR 0.03; 95% CI 0.002â-â0.279) and PFS (HR 0.09; 95% CI 0.02â-â0.36) than patients with the common alleles. The same effect on PFS was shown for patients with luminal A tumors (HR 0.19; 95% CI 0.05â-â0.84), whereas patients with luminal B tumors had a poorer PFS with two minor alleles (HR 2.13; 95% CI 1.02â-â4.40). The variant in rs3817198 has a prognostic effect particularly in the subgroup of patients with triple-negative BC, suggesting a possible link with immunomodulation and BC.
ABSTRACT
Acamprosate supports abstinence in some alcohol-dependent subjects, yet predictors of response are unknown. To identify response biomarkers, we investigated associations of abstinence length with polymorphisms in candidate genes in glycine and glutamate neurotransmission pathways and genes previously implicated in acamprosate response. Association analyses were conducted in the discovery sample of 225 alcohol-dependent subjects treated with acamprosate for 3 months in community-based treatment programs in the United States. Data from 110 alcohol-dependent males treated with acamprosate in the study PREDICT were used for replication of the top association findings. Statistical models were adjusted for relevant covariates, including recruitment site and baseline clinical variables associated with response. In the discovery sample, shorter abstinence was associated with increased intensity of alcohol craving and lower number of days between the last drink and initiation of acamprosate treatment. After adjustment for covariates, length of abstinence was associated with the GRIN2B rs2058878 (P=4.6 × 10(-5)). In the replication sample, shorter abstinence was associated with increased craving, increased depressive mood score and higher alcohol consumption. Association of abstinence length with GRIN2B rs2058878 was marginally significant (P=0.0675); as in the discovery sample, the minor A allele was associated with longer abstinence. Furthermore, rs2300272, which is in strong linkage disequilibrium with rs2058878, was also associated with abstinence length (P=0.049). This is the first report of a replicated association of genetic markers with the length of abstinence in acamprosate-treated alcoholics. Investigation of the underlying mechanisms of this association and its usefulness for individualized treatment selection should follow.
Subject(s)
Alcohol Deterrents/therapeutic use , Alcoholism/drug therapy , Alcoholism/genetics , Genetic Markers/genetics , Taurine/analogs & derivatives , Acamprosate , Adolescent , Adult , Aged , Aged, 80 and over , Female , Genetic Predisposition to Disease/genetics , Humans , Male , Middle Aged , Remission Induction , Taurine/therapeutic use , Time Factors , Treatment Outcome , Young AdultABSTRACT
We evaluated homologous recombination deficient (HRD) phenotypes in epithelial ovarian cancer (EOC) considering BRCA1, BRCA2, and RAD51C in a large well-annotated patient set. We evaluated EOC patients for germline deleterious mutations (n = 899), somatic mutations (n = 279) and epigenetic alterations (n = 482) in these genes using NGS and genome-wide methylation arrays. Deleterious germline mutations were identified in 32 (3.6%) patients for BRCA1, in 28 (3.1%) for BRCA2 and in 26 (2.9%) for RAD51C. Ten somatically sequenced patients had deleterious alterations, six (2.1%) in BRCA1 and four (1.4%) in BRCA2. Fifty two patients (10.8%) had methylated BRCA1 or RAD51C. HRD patients with germline or somatic alterations in any gene were more likely to be high grade serous, have an earlier diagnosis age and have ovarian and/or breast cancer family history. The HRD phenotype was most common in high grade serous EOC. Identification of EOC patients with an HRD phenotype may help tailor specific therapies.
Subject(s)
BRCA1 Protein/genetics , BRCA2 Protein/genetics , DNA-Binding Proteins/genetics , Neoplasms, Glandular and Epithelial/genetics , Ovarian Neoplasms/genetics , Base Sequence , Carcinoma, Ovarian Epithelial , DNA Methylation/genetics , Female , Homologous Recombination/genetics , Humans , Middle Aged , Mutation , Neoplasms, Glandular and Epithelial/classification , Neoplasms, Glandular and Epithelial/mortality , Ovarian Neoplasms/classification , Ovarian Neoplasms/mortality , Sequence Analysis, DNAABSTRACT
AIMS/HYPOTHESIS: Gestational exposures such as dietary changes can alter offspring phenotype through epigenetic modifications and promote increased risk for specific diseases, such as metabolic syndrome. We hypothesized that high-fat diet (HFD) during late gestation would lead increased risk for insulin resistance and hyperlipidemia via associated epigenetic alterations in tissue adipocytokine genes. METHODS: Offspring mice of mothers fed a HFD during late gestation (HFDO) were weighed and their food intake measured weekly till age 20 weeks at which time glucose and insulin tolerance tests, plasma lipid and adipocytokine levels were assessed, as well as mRNA expression in visceral fat. Adipocytokine gene methylation levels in visceral fat, liver and muscle were also assayed. RESULTS: HFDO mice had increased weight accrual and food intake, and exhibited insulin resistance, hyperlipidemia and hyperleptinemia, as well as hypoadiponectinemia. Furthermore, increased methylation of adiponectin and leptin receptor, and decreased methylation of leptin genes with unchanged glucagon-like peptide-1 methylation patterns emerged in HFDO mice. CONCLUSIONS: Taken together, late gestational HFD induces increased risk of metabolic syndrome in the progeny, which is coupled with hypoadiponectinemia as well as with leptin resistance, and concomitant presence of selective tissue-based epigenetic changes among adipocytokine genes.
Subject(s)
Adiponectin/deficiency , Adiponectin/metabolism , Diet, High-Fat , Metabolic Syndrome/metabolism , Metabolism, Inborn Errors/metabolism , Prenatal Exposure Delayed Effects/metabolism , Acetylation , Animals , Animals, Newborn , Body Weight , Epigenesis, Genetic , Female , Glucose Tolerance Test , Insulin/metabolism , Insulin Resistance , Leptin/metabolism , Liver/metabolism , Male , Mice , Mice, Inbred C57BL , Phenotype , Pregnancy , Time FactorsABSTRACT
OBJECTIVES: To identify venous thromboembolism (VTE) disease-susceptibility genes. PATIENTS AND METHODS: We performed in silico genome wide association scan (GWAS) analyses using genotype data imputed to approximately 2.5 million single-nucleotide polymorphisms (SNPs) from adults with objectively-diagnosed VTE (n=1503), and controls frequency matched on age and gender (n=1459; discovery population). Single-nucleotide polymorphisms exceeding genome-wide significance were replicated in a separate population (VTE cases, n=1407; controls, n=1418). Genes associated with VTE were re-sequenced. RESULTS: Seven SNPs exceeded genome-wide significance (P<5×10(-8)): four on chromosome 1q24.2 (F5 rs6025 [factor V Leiden], BLZF1 rs7538157, NME7 rs16861990 and SLC19A2 rs2038024) and three on chromosome 9q34.2 (ABO rs2519093 [ABO intron 1], rs495828, rs8176719 [ABO blood type O allele]). The replication study confirmed a significant association of F5, NME7 and ABO with VTE. However, F5 was the main signal on 1q24.2 as only ABO SNPs remained significantly associated with VTE after adjusting for F5 rs6025. This 1q24.2 region was shown to be inherited as a haplotype block. ABO re-sequencing identified 15 novel single nucleotide variations (SNV) in ABO intron 6 and the ABO 3' UTR that were strongly associated with VTE (P<10(-4)) and belonged to three distinct linkage disequilibrium (LD) blocks; none were in LD with ABO rs8176719 or rs2519093. Our sample size provided 80% power to detect odds ratios (ORs)=2.0 and 1.51 for minor allele frequencies=0.05 and 0.5, respectively (α=1×10(-8); 1% VTE prevalence). CONCLUSIONS: Apart from F5 rs6025, ABO rs8176719, rs2519093 and F2 rs1799963, additional common and high VTE-risk SNPs among whites are unlikely.
Subject(s)
Chromosomes, Human, Pair 1 , Chromosomes, Human, Pair 9 , Polymorphism, Single Nucleotide , Venous Thromboembolism/genetics , ABO Blood-Group System/genetics , Case-Control Studies , Computer Simulation , Factor V/genetics , Gene Frequency , Genetic Predisposition to Disease , Genome-Wide Association Study , Haplotypes , Humans , Linkage Disequilibrium , Logistic Models , Minnesota/epidemiology , Models, Genetic , Odds Ratio , Prevalence , Prothrombin/genetics , Risk Assessment , Risk Factors , Venous Thromboembolism/ethnology , White People/geneticsABSTRACT
The introduction of the Institute of Biomedical Science (IBMS) portfolio for pre-registration training in 2003 allowed universities to develop integrated (co-terminus) biomedical science BSc programmes. Students undertake structured placements within clinical pathology laboratories as part of their degree. The clinical training and professional development of students is undertaken by training officers (TOs), who are experienced Health Professions Council (HPC)-registered biomedical scientists and usually also members of the IBMS. This study aims to evaluate TOs' perceptions of these integrated degrees as a means of delivering pre-registration training for biomedical scientists. A questionnaire to collect quantitative data and be completed anonymously was sent to TOs, via staff at participating universities. Items considered TOs' perceptions in four categories: how well students fitted into the laboratory team, their professional and scientific development, the impact of delivering integrated degrees on service delivery, and the commitment to training students. Surveys took place in 2007, 2008 and 2009 and involved TOs taking students from 10, 14 and 17 universities each year, respectively. The response rates to the survey were 60% in 2007, 34% in 2008 and 12% in 2009. Participants were representative in terms of age, gender and pathology discipline and had a broad range of experience with students. The overall mean score for TOs perceptions was 3.38 in 2007 which increased significantly to 3.99 in 2009 (Kruskall Wallis test chi2 = 21.13, P<0.01). Mean scores in three of the four categories were positive in 2007, although the impact on service delivery was perceived negatively. In all areas, means were significantly greater in 2009. The results indicate that TOs view the integrated degrees favourably and are happy with the scientific and professional development of students. Although designing training sessions suitable for undergraduates took extra work initially, TOs are committed to delivering the training.
Subject(s)
Biomedical Technology/education , Education, Medical, Undergraduate/organization & administration , Adult , Attitude of Health Personnel , Female , Humans , Male , Medical Laboratory Personnel , Middle Aged , Program Evaluation , United KingdomABSTRACT
BACKGROUND: Venous thromboembolism (VTE) is highly heritable (estimated heritability [h(2)]=0.62) and likely to be a result of multigenic action. OBJECTIVE: To systematically test variation within genes encoding for important components of the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways for an independent association with VTE. METHODS: Non-Hispanic adults of European ancestry with objectively-diagnosed VTE, and age- and sex- matched controls, were genotyped for 13 031 single nucleotide polymorphisms (SNPs) within 764 genes. Analyses (n=12296 SNPs) were performed with plink using an additive genetic model and adjusted for age, sex, state of residence, and myocardial infarction or stroke. RESULTS: Among 2927 individuals, one or more SNPs within ABO, F2, F5, F11, KLKB1, SELP and SCUBE1 were significantly associated with VTE, including factor (F) V Leiden, prothrombin G20210A, ABO non-O blood type, and a novel association with ABO rs2519093 (OR=1.68, P-value=8.08×10(-16) ) that was independent of blood type. In stratified analyses, SNPs in the following genes were significantly associated with VTE: F5 and ABO among both genders and LY86 among women; F2, ABO and KLKB1 among FV Leiden non-carriers; F5, F11, KLKB1 and GFRA1 in those with ABO non-O blood type; and ABO, F5, F11, KLKB1, SCUBE1 and SELP among prothrombin G20210A non-carriers. The ABO rs2519093 population-attributable risk (PAR) exceeded that of FV Leiden and prothrombin G20210A, and the joint PAR of FV Leiden, prothrombin G20210A, ABO non-O and ABO rs2519093 was 0.40. CONCLUSIONS: Anticoagulant, procoagulant, fibrinolytic and innate immunity pathway genetic variation accounts for a large proportion of VTE among non-Hispanic adults of European ancestry.
Subject(s)
Genetic Variation , Hemostasis/genetics , Immunity, Innate/genetics , Venous Thromboembolism/etiology , Adult , Aged , Blood Coagulation/genetics , Disease Susceptibility , Female , Fibrinolysis/genetics , Genotype , Humans , Linkage Disequilibrium , Male , Middle Aged , Risk FactorsABSTRACT
BACKGROUND: Small-cell lung cancer (SCLC) carries the worst prognosis among lung cancer diagnoses. Combined radiation and chemotherapy is the standard of care; however, treatment outcomes vary. Variability in the rate at which chemotherapy agents are metabolized and in the capacity of repairing DNA damage has been hypothesized to be partly responsible for the treatment response variation. Genes in the glutathione metabolism and DNA repair pathways were tested through tag single-nucleotide polymorphisms (SNPs) to assess their association with survival in SCLC. PATIENTS AND METHODS: Blood DNA from 248 patients with primary SCLC was genotyped for 419 tag SNPs from 49 genes in the glutathione and DNA repair pathways. Association analyses with patient survival were carried out at single-SNP, whole-gene, and haplotype levels after adjusting for age, gender, tumor stage, treatment modalities, and smoking history. RESULTS: Among the 375 SNPs successfully genotyped, 21 SNPs, located on 11 genes, showed significant association with survival. Whole-gene analyses confirmed 3 of the 11 genes: GSS, ABCC2, and XRCC1. Haplotype analyses of these three genes identified haplotype combinations and genomic locations underlying the observed SNP associations. CONCLUSION: Genetic variations in genes involved in the glutathione and DNA repair pathways are associated with SCLC survival.
Subject(s)
Biomarkers, Tumor/genetics , DNA Repair/genetics , Glutathione/metabolism , Lung Neoplasms/genetics , Lung Neoplasms/mortality , Polymorphism, Single Nucleotide/genetics , Small Cell Lung Carcinoma/genetics , Small Cell Lung Carcinoma/mortality , Aged , DNA-Binding Proteins/genetics , Female , Genotype , Haplotypes/genetics , Humans , Lung Neoplasms/pathology , Male , Middle Aged , Multidrug Resistance-Associated Protein 2 , Multidrug Resistance-Associated Proteins/genetics , Prognosis , Small Cell Lung Carcinoma/pathology , Survival Rate , X-ray Repair Cross Complementing Protein 1ABSTRACT
BACKGROUND: Dysregulation of the cell cycle is a hallmark of many cancers including ovarian cancer, a leading cause of gynaecologic cancer mortality worldwide. METHODS: We examined single nucleotide polymorphisms (SNPs) (n=288) from 39 cell cycle regulation genes, including cyclins, cyclin-dependent kinases (CDKs) and CDK inhibitors, in a two-stage study. White, non-Hispanic cases (n=829) and ovarian cancer-free controls (n=941) were genotyped using an Illumina assay. RESULTS: Eleven variants in nine genes (ABL1, CCNB2, CDKN1A, CCND3, E2F2, CDK2, E2F3, CDC2, and CDK7) were associated with risk of ovarian cancer in at least one genetic model. Seven SNPs were then assessed in four additional studies with 1689 cases and 3398 controls. Association between risk of ovarian cancer and ABL1 rs2855192 found in the original population [odds ratio, OR(BB vs AA) 2.81 (1.29-6.09), P=0.01] was also observed in a replication population, and the association remained suggestive in the combined analysis [OR(BB vs AA) 1.59 (1.08-2.34), P=0.02]. No other SNP associations remained suggestive in the replication populations. CONCLUSION: ABL1 has been implicated in multiple processes including cell division, cell adhesion and cellular stress response. These results suggest that characterization of the function of genetic variation in this gene in other ovarian cancer populations is warranted.
Subject(s)
Cell Cycle/genetics , Genetic Predisposition to Disease , Ovarian Neoplasms/genetics , Polymorphism, Single Nucleotide , Cyclin-Dependent Kinases/genetics , Female , Humans , Ovarian Neoplasms/etiologyABSTRACT
The search for genetic variants associated with ovarian cancer risk has focused on pathways including sex steroid hormones, DNA repair, and cell cycle control. The Ovarian Cancer Association Consortium (OCAC) identified 10 single-nucleotide polymorphisms (SNPs) in genes in these pathways, which had been genotyped by Consortium members and a pooled analysis of these data was conducted. Three of the 10 SNPs showed evidence of an association with ovarian cancer at P< or =0.10 in a log-additive model: rs2740574 in CYP3A4 (P=0.011), rs1805386 in LIG4 (P=0.007), and rs3218536 in XRCC2 (P=0.095). Additional genotyping in other OCAC studies was undertaken and only the variant in CYP3A4, rs2740574, continued to show an association in the replication data among homozygous carriers: OR(homozygous(hom))=2.50 (95% CI 0.54-11.57, P=0.24) with 1406 cases and 2827 controls. Overall, in the combined data the odds ratio was 2.81 among carriers of two copies of the minor allele (95% CI 1.20-6.56, P=0.017, p(het) across studies=0.42) with 1969 cases and 3491 controls. There was no association among heterozygous carriers. CYP3A4 encodes a key enzyme in oestrogen metabolism and our finding between rs2740574 and risk of ovarian cancer suggests that this pathway may be involved in ovarian carcinogenesis. Additional follow-up is warranted.
Subject(s)
Cytochrome P-450 CYP3A/genetics , DNA Ligases/genetics , DNA-Binding Proteins/genetics , Genetic Predisposition to Disease , Ovarian Neoplasms/genetics , Polymorphism, Single Nucleotide/genetics , Adult , Aged , Case-Control Studies , Cohort Studies , DNA Ligase ATP , Female , Genotype , Heterozygote , Homozygote , Humans , Middle Aged , Neoplasm Invasiveness , Ovarian Neoplasms/pathology , Risk FactorsABSTRACT
The influence of genetic variations in SLC6A4 (serotonin transporter gene) on citalopram treatment of depression using the Sequenced Treatment to Relieve Depression (STAR*D) sample was assessed. Of primary interest were three previously studied polymorphisms: 1) the VNTR variation of the second intron, 2) the indel promoter polymorphism (5HTTLPR or SERT), and 3) a single nucleotide polymorphism (SNP) rs25531. Additionally, SLC6A4 was resequenced to identify new SNPs for exploratory analyses. DNA from 1914 subjects in the STAR*D study were genotyped for the intron 2 VNTR region, the indel promoter polymorphism, and rs25531. Associations of these variants with remission of depressive symptoms were evaluated following citalopram treatment. In white non-Hispanic subjects, variations in the intron 2 VNTR (point-wise P = 0.041) and the indel promoter polymorphism (point-wise P = 0.039) were associated with remission following treatment with citalopram. The haplotype composed of the three candidate loci was also associated with remission, with a global p-value of 0.040 and a maximum statistic simulation p-value of 0.0031 for the S-a-12 haplotype, under a dominant model. One SNP identified through re-sequencing the SLC6A4 gene, Intron7-83-TC, showed point-wise evidence of association, which did not remain significant after correction for the number of SNPs evaluated in this exploratory analysis. No associations between these SLC6A4 variations and remission were found in the white Hispanic or black subjects. These findings suggest that multiple variations in the SLC6A4 gene are associated with remission in white non-Hispanic depressed adults treated with citalopram. The mechanism of action of these variants remains to be determined.
Subject(s)
Antidepressive Agents, Second-Generation/therapeutic use , Citalopram/therapeutic use , Depressive Disorder, Major/genetics , Selective Serotonin Reuptake Inhibitors/therapeutic use , Serotonin Plasma Membrane Transport Proteins/genetics , Adult , Black or African American/genetics , Alleles , Clinical Trials as Topic , Depressive Disorder, Major/drug therapy , Female , Gene Frequency , Genetic Variation , Haplotypes , Hispanic or Latino/genetics , Humans , Introns , Linkage Disequilibrium , Male , Middle Aged , Minisatellite Repeats , Polymorphism, Single Nucleotide , Promoter Regions, Genetic , Remission Induction , Sequence Analysis, DNA , Treatment Outcome , White People/geneticsABSTRACT
BACKGROUND: Aggregation and fibrillization of the alpha-synuclein protein (encoded by the SNCA gene) may represent key events in the pathogenesis of Parkinson disease (PD). Variability in the length of a dinucleotide repeat sequence (REP1) within the SNCA promoter confers susceptibility to sporadic PD. Pesticide exposures may also confer susceptibility to PD. Our objective was to test possible joint effects of SNCA REP1 genotypes and pesticide exposures on the risk of PD. METHODS: This was a case-control study. Cases were recruited prospectively from the Department of Neurology of the Mayo Clinic, Rochester, MN, after June 1, 1996. The control subjects included unaffected siblings of cases and unrelated population control subjects. We assessed pesticide exposures by telephone interview and genotyped SNCA REP1. Odds ratios (ORs) and 95% CIs were determined using conditional logistic regression models. RESULTS: There were 833 case-control pairs. We observed an increased risk of PD with increasing SNCA REP1 bp length (OR, 1.18 for each score unit; 95% CI, 1.02-1.37; p = 0.03). Pesticide exposures were associated with PD in younger subjects only (lowest quartile of age at study, Subject(s)
Parkinson Disease, Secondary/chemically induced
, Parkinson Disease, Secondary/genetics
, Pesticides/adverse effects
, alpha-Synuclein/genetics
, Adult
, Age Factors
, Aged
, Aged, 80 and over
, Case-Control Studies
, Dinucleotide Repeats/genetics
, Female
, Genetic Variation
, Genotype
, Humans
, Male
, Middle Aged
, Prospective Studies
, Risk Factors
ABSTRACT
BACKGROUND: Mutations of myelin protein zero (MPZ) may cause inherited neuropathy with variable expression. OBJECTIVE: To report phenotypic variability in a large American kindred with MPZ mutation His39Pro. PATIENTS: Genetic testing was performed on 77 family members and 200 controls. Clinical and electrophysiological field study assessments were available for review in 47 family members. RESULTS: His39Pro was found in all 10 individuals prospectively identified with neuropathy. 200 normal controls were without mutation. Symptoms of neuropathy began in adulthood and were slowly progressive except for one acute-onset painful sensory neuropathy. Associated features included premature hearing loss (n = 7), nocturnal restless leg symptoms (n = 8) and multiple sclerosis in one. CONCLUSIONS: MPZ mutation His39Pro may be associated with acute-onset neuropathy, early-onset hearing loss and restless legs. The relationship with multiple sclerosis in the proband remains uncertain.
Subject(s)
Hearing Loss/genetics , Multiple Sclerosis/genetics , Myelin P0 Protein/genetics , Adult , Age of Onset , Child, Preschool , DNA Mutational Analysis , Female , Hereditary Sensory and Autonomic Neuropathies/genetics , Histidine , Humans , Male , Middle Aged , Pedigree , Phenotype , Proline , Restless Legs Syndrome/geneticsABSTRACT
BACKGROUND: The variable clinical features of hereditary sensory and autonomic neuropathy (HSAN I) suggest heterogeneity. Some cases of idiopathic sensory neuropathy could be caused by missense mutations of SPTLC1 and RAB7 and not be recognised as familial. OBJECTIVE: To screen persons with dominantly inherited HSAN I and others with idiopathic sensory neuropathies for known mutations of SPTLC1 and RAB7. PATIENTS: DNA was examined from well characterised individuals of 25 kindreds with adult onset HSAN I for mutations of SPTLC1 and RAB7; 92 patients with idiopathic sensory neuropathy were also screened for known mutations of these genes. RESULTS: Of the 25 kindreds, only one had a mutation (SPTLC1 399T-->G). This kindred, and 10 without identified mutations, had prominent mutilating foot injuries with peroneal weakness. Of the remainder, 12 had foot insensitivity with injuries but no weakness, one had restless legs and burning feet, and one had dementia with hearing loss. No mutation of RAB7 was found in any of these. No known mutations of SPTLC1 or RAB7 were found in cases of idiopathic sensory neuropathy. CONCLUSIONS: Adult onset HSAN I is clinically and genetically heterogeneous and further work is required to identify additional genetic causes. Known SPTLC1or RAB7 mutations were not found in idiopathic sensory neuropathy.
Subject(s)
Acyltransferases/genetics , DNA Mutational Analysis , Genes, Dominant , Hereditary Sensory and Autonomic Neuropathies/genetics , rab GTP-Binding Proteins/genetics , Adult , DNA Primers/genetics , Diagnosis, Differential , Exons , Fabry Disease/diagnosis , Fabry Disease/genetics , Female , Genetic Carrier Screening , Genotype , Hereditary Sensory and Autonomic Neuropathies/diagnosis , Humans , Male , Molecular Sequence Data , Open Reading Frames , Pedigree , Polyneuropathies/diagnosis , Polyneuropathies/genetics , Sequence Analysis, DNA , Serine C-Palmitoyltransferase , rab7 GTP-Binding ProteinsABSTRACT
SUMMARY: Encephalopathy is a poorly characterized complication of hematopoietic stem cell transplantation (HSCT). No comprehensive report of encephalopathy exists for children, and the literature contains only a few for adults. We analyzed a large cohort of 405 pediatric patients who underwent allogeneic HSCT during a 10-year period and identified 26 patients (6.4%) who experienced encephalopathy. Identifiable causes of encephalopathy included infection (n=5), single or multiorgan failure (n=4), medication-related complications (n=3), nonconvulsive seizures (n=4), acute disseminated encephalomyelitis (n=2), thrombotic thrombocytopenic purpura (n=2), and stroke (n=1). We were unable to identify the etiology of encephalopathy in five (19%) patients. The prognosis for pediatric patients with encephalopathy was poor: only four (15%) experienced complete neurologic recovery, and 10 (38%) patients experienced partial recovery with residual neurologic deficits. Nine (35%) patients with complete or partial recovery survive long term. A total of 17 patients died; one died of progressive encephalopathy, and 16 died of either relapse of primary disease or toxicity. MRI, CSF analysis including molecular testing for infectious pathogens, and brain biopsy were helpful in obtaining a diagnosis in most of our patients. However, a standardized approach to accurate and timely diagnosis and treatment is needed to improve outcome in these patients.
Subject(s)
Brain Diseases/diagnosis , Brain Diseases/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Adolescent , Adult , Algorithms , Brain Diseases/epidemiology , Cause of Death , Child , Child, Preschool , Female , Hematologic Diseases/complications , Hematologic Diseases/mortality , Hematologic Diseases/therapy , Humans , Infant , Male , Prognosis , Retrospective Studies , Survival Rate , Transplantation, HomologousABSTRACT
Peritransplant toxicity and a delay in effective immune reconstitution have limited the utility of alternate donor transplantation for children with refractory severe aplastic anemia. We have assessed the effectiveness of infusing large numbers of highly purified haploidentical CD34+ cells after immunoablative conditioning in three patients who had failed intensive immunosuppression, lacked unrelated donors, and had active or recent serious infections. One patient rejected the first infusion, but engrafted after a second infusion from the same donor. This patient died 4 months after hematopoietic stem cell transplantation with no evidence of lymphoid reconstitution. Two patients experienced mixed chimerism requiring treatment with antibodies and/or donor lymphocyte infusion. Both currently survive more than 1 year after transplantation with normal blood counts, 100% donor engraftment, effective lymphoid reconstitution, and no chronic graft-versus-host disease. We observed functional thymopoiesis as measured by lymphocyte immunophenotyping, T cell receptor excision circles and T cell receptor Vbeta spectratyping complexity analysis. Further study is required to validate the initial promise of these preliminary observations.
Subject(s)
Anemia, Aplastic/therapy , Hematopoietic System/physiology , Lymphatic System/physiology , Peripheral Blood Stem Cell Transplantation/methods , Regeneration , Antigens, CD34 , B-Lymphocytes/immunology , Child , Child, Preschool , Female , Graft Survival , Haplotypes , Histocompatibility Testing , Humans , Immunoglobulins/biosynthesis , Male , Peripheral Blood Stem Cell Transplantation/standards , Prospective Studies , Salvage Therapy/methods , T-Lymphocytes/immunology , Thymus Gland/physiology , Transplantation Chimera , Transplantation, HomologousABSTRACT
Hemorrhagic cystitis (HC) is a well-documented adverse event experienced by patients undergoing hematopoietic stem cell transplantation. When severe, HC causes significant morbidity, leads to renal complications, prolongs hospitalization, increases health-care costs, and occasionally contributes to death. We retrospectively studied the medical records of 245 children undergoing an initial allogeneic bone marrow transplantation for malignant disease at St. Jude Children's Research Hospital between 1992 and 1999 to describe the clinical course of HC in all patients and to identify the risk factors for HC in this cohort. Conditioning regimens included cyclophosphamide, cytarabine, and total body irradiation. Grafts from unrelated or mismatched related donors were depleted of T lymphocytes, whereas matched sibling grafts were unmanipulated. All patients received cyclosporine as prophylaxis for graft-versus-host disease. Recipients of grafts from matched siblings also received pentoxifylline or short-course methotrexate. Severe HC developed in 27 patients (11.0%). The median duration of HC was 73 days (range, 5-619 days); 12 patients had ongoing HC at the time of death. In univariate analyses, patients were at increased risk of severe HC if they were male (P =.021) or had received T cell-depleted grafts (P =.017), grafts from unrelated donors (P =.021), a lower total nucleated cell dose (P =.032), or antithymocyte globulin (P =.0446). Multiple regression analysis revealed male sex (beta =.97; P =.027) and unrelated donor graft recipients (beta =.83; P =.039) to be significant factors.
Subject(s)
Bone Marrow Transplantation/adverse effects , Cystitis/etiology , Hemorrhagic Disorders/etiology , Acute Disease , Adolescent , Adult , Child , Child, Preschool , Chronic Disease , Family , Graft vs Host Disease/epidemiology , Graft vs Host Disease/prevention & control , Hemorrhagic Disorders/epidemiology , Humans , Infant , Living Donors , Lymphocyte Transfusion , Middle Aged , Neoplasms/drug therapy , Retrospective Studies , Risk Factors , Tissue Donors , Transplantation, Homologous , Treatment OutcomeABSTRACT
Pancreatic beta-cells have low activities of the antioxidant enzyme catalase. Nitric oxide interacts with the haem group of catalase inhibiting its activity. We have studied the activity of catalase in beta-cells under conditions mimicking prediabetes and in which nitric oxide is generated from cytokine treatment in vitro. We also studied whether there is regulation of catalase enzyme activity by nitric oxide at the protein or gene expression level. RINm5F insulin-producing cells, treated for 24 h with cytokines, showed increased medium nitrite production (17+/-2.2 vs 0.3+/-0.2 pmol/ micro g protein) and significantly decreased cellular catalase activity (42.4+/-4.5%) compared with control cells. A similar reduction was seen in catalase-overexpressing RIN-CAT cells and in rat or human pancreatic islets of Langerhans. Catalase activity was also suppressed by the long-acting nitric oxide donor diethylenetriamine/nitric oxide adduct (Deta-NO) and this inhibition was reversible. The inhibition of catalase activity by cytokines in RINm5F cells was significantly reversed by the addition of the nitric oxide synthase 2 (NOS2) inhibitors nitro monomethylarginine or N-(3-(aminomethyl)benzyl)acetamidine (1400W). Protein expression was found to be unchanged in cytokine- or Deta-NO-treated RINm5F cells, while mRNA expression was marginally increased. We have shown that inhibition of catalase activity by cytokines is nitric oxide dependent and propose that this inhibition may confer increased susceptibility to cytokine- or nitric oxide-induced cell killing.
Subject(s)
Catalase/metabolism , Cytokines/pharmacology , Insulinoma/enzymology , Nitric Oxide/pharmacology , Pancreatic Neoplasms/enzymology , Amidines/pharmacology , Animals , Benzylamines/pharmacology , Cell Death/physiology , Enzyme Activation/physiology , Enzyme Inhibitors/pharmacology , Humans , Insulin/metabolism , Islets of Langerhans/enzymology , Nitric Oxide Synthase/metabolism , Nitric Oxide Synthase Type II , RNA, Messenger/genetics , Rats , Triazenes/pharmacology , Tumor Cells, CulturedABSTRACT
The histiocytoses are rare disorders of antigen-processing phagocytic or antigen-presenting cells. Allogeneic bone marrow transplantation (BMT) can be curative of these disorders. We report a series of five children with Langerhans cell histiocytosis (n=2) or hemophagocytic lymphohistiocytosis (n=3), who received allogeneic BMT with a total body irradiation (TBI)-containing regimen (TBI, cytarabine, and cyclophosphamide) at our institution between 1995 and 2000. One of these patients received busulfan, cyclophosphamide, and etoposide for the first of two BMTs. All grafts except one (a matched sibling-donor graft) were T-cell-depleted grafts from unrelated donors. All received cyclosporine graft-versus-host disease (GvHD) prophylaxis; the recipient of the matched sibling graft also received methotrexate. Three patients engrafted at a median of 24 days after transplantation. The patient who did not receive TBI experienced primary graft failure and recurrent disease. After the TBI-containing conditioning regimen was given, a second transplant engrafted on day +17. One patient with concurrent myelodysplastic syndrome died of toxicity on day +33 without evidence of engraftment. No acute or chronic GvHD was observed. Four patients survive disease-free, a median of 63 months after transplantation, all with Lansky performance scores of 100. We conclude that a conditioning regimen containing TBI but not etoposide is effective in allogeneic BMT for children with histiocytic diseases.
Subject(s)
Bone Marrow Transplantation/statistics & numerical data , Histiocytosis, Langerhans-Cell/surgery , Transplantation Conditioning/methods , Whole-Body Irradiation/methods , Bone Marrow Transplantation/adverse effects , Child , Follow-Up Studies , Graft vs Host Disease/epidemiology , Humans , Lymphocyte Depletion/methods , Retrospective Studies , T-Lymphocytes/immunology , Time Factors , Treatment OutcomeABSTRACT
T-cell dysfunction is thought to be central to the immunodeficiency state seen in patients with the Wiskott-Aldrich syndrome (WAS). Aspects of the WAS phenotype have been corrected in other cell types on introduction of the normal WAS protein (WASP), but the potential for correction of the T-cell defects has not been evaluated. Here we demonstrate that an oncoretroviral vector encoding WASP and green fluorescent protein (GFP), and pseudotyped with the RD114 envelope protein, efficiently transduces primary human T cells derived from WAS patients. Transcription initiated at the oncoretroviral long terminal repeat (LTR) results in levels of WASP that, while lower than those seen in normal control T cells, resulted in correction of the deficient proliferative response to T-cell receptor (TCR) stimulation characteristic of WAS. IL2 secretion after TCR stimulation was partially corrected. Control primary T cells transduced with the same vector responded normally to TCR stimulation, and showed no increase in WASP expression. The demonstration that correction of T cell defects can be achieved by gene transfer supports continued efforts to develop gene therapy for WAS.